UCB’s efforts to build a franchise of therapies for muscle-wasting disease generalised myasthenia gravis have taken another step forwards after the CHMP recommended approv
Belgian biopharma UCB has been given the green light by the FDA for Zilbrysq as a treatment for generalised myasthenia gravis (gMG), one of two drugs that the company hope
AstraZeneca's Soliris has become the first approved treatment in the EU for children and adolescents with generalised myasthenia gravis, a disorder that causes weakness in
The FDA has become the first global regulator to approve UCB’s Rystiggo, a treatment for generalised myasthenia gravis that the company says is the only drug that can be u
The market for drugs to treat the muscle-wasting disease generalised myasthenia gravis (gMG) is getting more crowded, and Argenx has just claimed an FDA approval that coul